Research and analysis

ACRE advice: prostate cancer vaccine trial

The Advisory Committee on Releases to the Environment's advice on an application for a trial of a genetically modified cancer vaccine.

• From: Advisory Committee on Releases to the Environment
• Published: 4 January 2013

Documents

Advice on an application for deliberate release of a GMO: BN ImmunoTherapeutics

PDF, 116 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document is the Advisory Committee on Releases to the Environment’s (ACRE) advice to government in considering a request from BN ImmunoTherapeutics for a clinical trial of a genetically modified (GM) vaccine.

The trial would be part of the company’s research into prostate cancer and based in Northern Ireland.

The committee decided that the trial would have no risk to human health or the environment, and recommended that the application should be approved.

Published 4 January 2013